SYNERGY™
Everolimus-Eluting Platinum Chromium Coronary Stent System
3-month DAPT in High Bleeding Risk (HBR) patients undergoing PCI with the SYNERGY BP-DES
Studies the safety of discontinuing DAPT at 3-months in this HBR patient population using the SYNERGY BP-DES.*
Trial Design
- Prospective, multicenter, single-arm trial
- 2,009 patients with significant bleeding risks at 110 global sites
- Primary endpoint data collected from 1,487 patients eligible to discontinue DAPT at 3-months.
Clinical Outcomes at 12-months Post-DAPT Discontinuation
Clinical Outcomes
Outstanding evidence across trials
Real-World Studies
Low event rates in real-world studies
Early Healing
Advanced design for optimal healing